Delivery Order SPE2DB20D1100-SPE2DB25FE1T0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $32,444.88 and firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of September 2, 2025, with performance to be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a contract ceiling value of $44,612.34. This firm fixed-price delivery order, with an ultimate completion date of September 18, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a ceiling value of $1,709.46 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors, with a contract ceiling value of $6,564.18. This is a firm fixed-price delivery order with no set-aside designation, completed competitively. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with a scheduled completion date of August 14, 2025. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors, with a contract ceiling value of $10,915.00. This is a firm fixed price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a $22,639.98 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract, which is non-set-aside and firm fixed price, will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a $5,128.38 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed price, non-set-aside contract with a completion date of July 23, 2025, and performance location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors, with a ceiling value of $1,709.46. This firm fixed-price delivery order, which represents a non-set-aside competitive award, is scheduled for completion by August 26, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors with a contract ceiling value of $8,451.19. The contract represents a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and utilizes no set-aside designation. This award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1T0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of approximately $12,015. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 21, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $1 billion prime vehicle valued through December 2026 that provides comprehensive global pharmaceutical support to military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor supplying brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Dupixent is a specialty biologic medication used to treat eczema, asthma, and other allergic and inflammatory conditions, representing the type of specialized pharmaceutical commodity the company regularly delivers through its federal contract portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.0k | 8/20/25 |